LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC boosted its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 20.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,458 shares of the company’s stock after buying an additional 935 shares during the quarter. SG Americas Securities LLC’s holdings in LENZ Therapeutics were worth $158,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of LENZ. Squarepoint Ops LLC bought a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $181,000. MetLife Investment Management LLC bought a new stake in LENZ Therapeutics during the third quarter valued at $182,000. GSA Capital Partners LLP bought a new position in shares of LENZ Therapeutics in the 3rd quarter worth about $246,000. Jane Street Group LLC acquired a new position in shares of LENZ Therapeutics in the 3rd quarter valued at about $286,000. Finally, Barclays PLC lifted its holdings in LENZ Therapeutics by 273.1% in the third quarter. Barclays PLC now owns 16,463 shares of the company’s stock worth $391,000 after acquiring an additional 12,051 shares during the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

Shares of NASDAQ:LENZ opened at $25.28 on Monday. LENZ Therapeutics, Inc. has a 12 month low of $14.42 and a 12 month high of $38.93. The stock’s 50 day moving average price is $28.45 and its 200 day moving average price is $26.92.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, LENZ Therapeutics has a consensus rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.